Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study
Authors:
- Marcelo KremenchutzkyMKMarcelo Kremenchutzky
- Paul O’cOnnorPOPaul O’cOnnor
- Reinhard HohlfeldRHReinhard Hohlfeld
- Lixin Zhang-AubersonLZLixin Zhang-Auberson
- Philipp von RosenstielPRPhilipp von Rosenstiel
- Xiangyi MengXMXiangyi Meng
- Augusto GrinspanAGAugusto Grinspan
- Ron HashmonayRHRon Hashmonay
- Ludwig KapposLKLudwig Kappos
Open Access
- 1 May 2014
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 3 (3) , 341-349
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyThe Lancet Neurology, 2012
- Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence ProjectEuropean Neurology, 2011
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 2010
- Medication adherence with disease modifying treatments for multiple sclerosis among US employeesJournal of Medical Economics, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosisMultiple Sclerosis Journal, 2009
- Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in ArgentinaEuropean Journal of Neurology, 2008
- Clinical course after change of immunomodulating therapy in relapsing–remitting multiple sclerosisEuropean Journal of Neurology, 2006
- Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)European Journal of Neurology, 2005